Webinar Overview
All new oncology therapeutics must be evaluated at a preclinical stage in pediatric cancers before being approved by the FDA, per the recently implemented RACE Act. The lack of relevant models and guidelines for pediatric cancer therapies has made navigating this requirement difficult. However, the new ITCCP4 pediatric PDX collection provides a growing number of well-annotated oncology therapy models.
This webinar addresses the problems of outstanding clinical trials for pediatric cancers, with a focus on brain tumors, and provide alternatives for new investigational preclinical drug programs (IND). It also highlights the status of the ITCCP4 pediatric PDX model collection, now available to the scientific community.
You will learn about:
- Feasibility and robustness of a tumor-tracking optical imaging system in PDX models
- Single mouse trial as a screening tool to characterize PDX cohorts and identify the most efficacious compounds in vivo to overcome the lack of clinical trials for pediatric cancers
- The preclinical validation set, available not only for the PDX, but for the donor patient as well
Webinar Presenter
Julia Schueler, DVM, PhD
Research Director, Therapeutic Area Lead
Charles River